Oscar Tahuahua, Medical Oncology fellow at the National Cancer Institute of Mexico, posted on X:
“Larotrectinib as 1L for TRK fusion cancers (n=101)
- ORR 77%, CR/pCR 47%, PFS 61 mo, 5yr OS 76%.
- ORR 90% in children, 68% in adults. Best in locally advanced (ORR 90%). Mostly grade 1–2 AEs.
- Wait and see-safe in pediatrics, with successful rechallenge.”
Title: Efficacy and safety of larotrectinib as first-line treatment for patients with TRK fusion cancer
Authors: D.S. Hong, R.-H. Xu, L. Shen, M.P. Dierselhuis, D. Orbach, R. McDermott, A. Italiano, M. Tahara, V. Bernard-Gauthier, N. Neu, C.E. Mussi, E. De La Cuesta, T.W. Laetsch, A. Drilon
Read The Full Article at ESMO Open.
Learn more about Oscar Tahuahua on OncoDaily.